<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00257686</url>
  </required_header>
  <id_info>
    <org_study_id>NK-104-306</org_study_id>
    <nct_id>NCT00257686</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients</brief_title>
  <official_title>Study Of Pitavastatin 1 Mg Vs. Pravastatin 10 Mg, Pitavastatin 2 Mg Vs. Pravastatin 20 Mg And Pitavastatin 4 Mg Vs. Pravastatin 40 Mg (Following Up-Titration) In Elderly Patients With Primary Hypercholesterolemia Or Combined Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Europe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Europe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of pitavastatin with that of
      pravastatin in elderly patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a wash-out dietary lead-in period, patients will receive either Preavastatin or
      Pitavastatin during 12 weeks, in order to establish the efficacy of pitavastatin in reducing
      cholesterol levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Percent change from baseline in low density cholesterol (LDL-C)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in TC</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Percent change from baseline in total cholesterol (TC)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">962</enrollment>
  <condition>Hypercholesterolemia or Combined Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Pitavastatin 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 1 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pravastatin 10 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 2 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pravastatin 20 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 4 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pravastatin 40 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <arm_group_label>Pitavastatin 1 mg</arm_group_label>
    <arm_group_label>Pitavastatin 2 mg</arm_group_label>
    <arm_group_label>Pitavastatin 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <arm_group_label>Pravastatin 10 mg</arm_group_label>
    <arm_group_label>Pravastatin 20 mg</arm_group_label>
    <arm_group_label>Pravastatin 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and postmenopausal females (aged 65 years and older

          -  Eligible, able to participate, have given informed consent

          -  Must have been following a restrictive diet

          -  Diagnosis of primary hypercholesterolemia or combined dyslipidemia

          -  Serum CK must be less than or equal to 1.5 x ULRR at 2 of 3 permitted evaluations
             between Week -4 and -1

          -  Agree to be available

        Exclusion Criteria

          -  Homozygous familial hypercholesterolemia

          -  Conditions which may cause secondary dyslipidemia

          -  Uncontrolled diabetes mellitus (HbA1c &gt;8%).

          -  Any condition which might significantly alter the absorption, distribution,
             metabolism, or excretion of any drug.

          -  History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury

          -  Liver injury

          -  Impaired renal function

          -  Current obstruction of the urinary tract or difficulty in voiding due to mechanical as
             well as inflammatory conditions, which is likely to require intervention during the
             course of the study or is regarded as clinically meaningful

          -  Serum CK &gt;5 x ULRR without clinical explanation

          -  Uncontrolled hypothyroidism defined as TSH &gt;ULRR

          -  Any severe acute illness or severe trauma in the last 3 months prior to Visit 1

          -  Major surgery, 3 months prior to Visit 1

          -  Significant CVD prior to randomization

          -  Evidence of symptomatic heart failure, gross cardiac enlargement; significant heart
             block or cardiac arrhythmias. History of uncontrolled complex ventricular arrhythmias,
             uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias
             with a ventricular response rate of &gt; 100 beats per minute at rest.

          -  Left ventricular ejection fraction &lt;0.25;

          -  History of symptomatic cerebrovascular disease

          -  Any other conditions at the discretion of the investigator

          -  Known HIV infection

          -  Poorly controlled or uncontrolled hypertension

          -  Prior or current known muscular or neuromuscular disease of any type;

          -  Neoplastic disease

          -  Drug abuse or continuous consumption of more than 65 mL pure alcohol per day

          -  Exposure to any investigational new drug within 30 days of study entry or ingestion of
             any drug known to be toxic to a major organ system

          -  Current or recent use of supplements known to alter lipid metabolism

          -  History of hypersensitivity to other HMG-CoA reductase inhibitors;

          -  Concomitant medication not permitted

          -  Resistant to lipid-lowering medications. Known hypersensitivity or intolerance to any
             lipid lowering agent

          -  Excessive obesity

          -  Any factor which makes regular clinic attendance in the morning impractical ---Signs
             of mental dysfunction or other factors likely to limit ability to cooperate with the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dragos Budinski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCBR A/S</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR A/S</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologische Gemeinschaftspraxis Prof. Reifart</name>
      <address>
        <city>Bad Soden / Taunus</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Boenninghoff</name>
      <address>
        <city>Beckum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GWT-TUK mbH, Zentrum fur Klinische Studien</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Krause, Th. Menke</name>
      <address>
        <city>Goch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innere Medizin I / Medizinische Klinik</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis H. Holz Dr. med, K. W. Klingl</name>
      <address>
        <city>Lampertheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZET-Studien GmbH Leipzing</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Wachter</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Melcherstaette</name>
      <address>
        <city>Melcherstaette</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler</name>
      <address>
        <city>Messkirch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft im Kleinen Biergrund</name>
      <address>
        <city>Offenbach/M</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Melcherstaette</name>
      <address>
        <city>Stuhr-Brinkum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Drs. Mockesch</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermed Institud Fur Klinische Forschung und Arzn</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Emden, Frank Drewes</name>
      <address>
        <city>Worpswede</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Soroka Medical Center</name>
      <address>
        <city>Beersheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine A, Rambal Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Research, Hadassah University Hospital</name>
      <address>
        <city>Jerusalem Ein Kerem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Hospital</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Hadassah Medical Center</name>
      <address>
        <city>Mount Scopus Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Rivka Sieff Medical Center</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Metabolic Diseases</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institue of Lipid &amp; Atherosclerosis Research</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Oost</name>
      <address>
        <city>ES Velp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Noord</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vasculair Onderzoek Centrum Hoorn</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Leiden</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Nijmegen</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer ziekenhuis</name>
      <address>
        <city>Sliedrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Breda</name>
      <address>
        <city>VL Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivierenland Tiel</name>
      <address>
        <city>WP Tiel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Zoetermeer</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer ziekenhuis</name>
      <address>
        <city>Zwijndrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oldfield Surgery</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's Surgery</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pulteney Practice</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Clinical Research Centre</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stonehill Medical Center</name>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chorley Clinical Research Centre</name>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saltash Health Center</name>
      <address>
        <city>Cornwall</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gomersal Lane Surgery</name>
      <address>
        <city>Dronfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townhead Research</name>
      <address>
        <city>Irvine</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crosby Clinical Research Centre</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Symons Medical Center</name>
      <address>
        <city>Maidenhead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Clinical Research Centre</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenwood Medical Center</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reading Clinical Research Centre</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elm Lane Surgery</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brook Lane Surgery</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Road Medical Center</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowden Medical Partnership</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Porch Surgery</name>
      <address>
        <city>Wiltshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burns Medical Practice</name>
      <address>
        <city>Yorkshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2005</study_first_submitted>
  <study_first_submitted_qc>November 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2005</study_first_posted>
  <results_first_submitted>August 26, 2009</results_first_submitted>
  <results_first_submitted_qc>December 11, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2010</results_first_posted>
  <last_update_submitted>March 9, 2010</last_update_submitted>
  <last_update_submitted_qc>March 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Neil Hounslow</name_title>
    <organization>Kowa Research Europe</organization>
  </responsible_party>
  <keyword>Kowa</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>combined</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>elderly</keyword>
  <keyword>pitavastatin</keyword>
  <keyword>NK-104</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pitavastatin 1 mg</title>
          <description>Pitavastatin 1 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Pravastatin 10 mg</title>
          <description>Pravastatin 10 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Pitavastatin 2 mg</title>
          <description>Pitavastatin 2 mg once daily</description>
        </group>
        <group group_id="P4">
          <title>Pravastatin 20 mg</title>
          <description>Pravastatin 20 mg once daily</description>
        </group>
        <group group_id="P5">
          <title>Pitavastatin 4 mg</title>
          <description>Pitavastatin 4 mg once daily</description>
        </group>
        <group group_id="P6">
          <title>Pravastatin 40 mg</title>
          <description>Pravastatin 40 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="226"/>
                <participants group_id="P4" count="99"/>
                <participants group_id="P5" count="216"/>
                <participants group_id="P6" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="207">Subjects who received at least one dose of study medication</participants>
                <participants group_id="P2" count="103">Subjects who received at least one dose of study medication</participants>
                <participants group_id="P3" count="224">Subjects who received at least one dose of study medication</participants>
                <participants group_id="P4" count="96">Subjects who received at least one dose of study medication</participants>
                <participants group_id="P5" count="210">Subjects who received at least one dose of study medication</participants>
                <participants group_id="P6" count="102">Subjects who received at least one dose of study medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="208"/>
                <participants group_id="P4" count="88"/>
                <participants group_id="P5" count="194"/>
                <participants group_id="P6" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pitavastatin 1 mg</title>
          <description>Pitavastatin 1 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Pravastatin 10 mg</title>
          <description>Pravastatin 10 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Pitavastatin 2 mg</title>
          <description>Pitavastatin 2 mg once daily</description>
        </group>
        <group group_id="B4">
          <title>Pravastatin 20 mg</title>
          <description>Pravastatin 20 mg once daily</description>
        </group>
        <group group_id="B5">
          <title>Pitavastatin 4 mg</title>
          <description>Pitavastatin 4 mg once daily</description>
        </group>
        <group group_id="B6">
          <title>Pravastatin 40 mg</title>
          <description>Pravastatin 40 mg once daily</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="224"/>
            <count group_id="B4" value="96"/>
            <count group_id="B5" value="210"/>
            <count group_id="B6" value="102"/>
            <count group_id="B7" value="942"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="224"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="210"/>
                    <measurement group_id="B6" value="102"/>
                    <measurement group_id="B7" value="942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="4.60"/>
                    <measurement group_id="B2" value="70.5" spread="4.61"/>
                    <measurement group_id="B3" value="70.5" spread="4.49"/>
                    <measurement group_id="B4" value="69.9" spread="4.51"/>
                    <measurement group_id="B5" value="70.2" spread="4.10"/>
                    <measurement group_id="B6" value="70.2" spread="4.94"/>
                    <measurement group_id="B7" value="70.2" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="121"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="89"/>
                    <measurement group_id="B6" value="60"/>
                    <measurement group_id="B7" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C</title>
        <description>Percent change from baseline in low density cholesterol (LDL-C)</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 1 mg</title>
            <description>Pitavastatin 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Pravastatin 10 mg</title>
            <description>Pravastatin 10 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 2 mg</title>
            <description>Pitavastatin 2 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Pravastatin 20 mg</title>
            <description>Pravastatin 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Pitavastatin 4 mg</title>
            <description>Pitavastatin 4 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Pravastatin 40 mg</title>
            <description>Pravastatin 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C</title>
          <description>Percent change from baseline in low density cholesterol (LDL-C)</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="210"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.43" spread="11.833"/>
                    <measurement group_id="O2" value="-22.41" spread="14.051"/>
                    <measurement group_id="O3" value="-38.99" spread="13.069"/>
                    <measurement group_id="O4" value="-28.83" spread="11.054"/>
                    <measurement group_id="O5" value="-44.31" spread="13.695"/>
                    <measurement group_id="O6" value="-33.98" spread="14.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in TC</title>
        <description>Percent change from baseline in total cholesterol (TC)</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin 1 mg</title>
            <description>Pitavastatin 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Pravastatin 10 mg</title>
            <description>Pravastatin 10 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Pitavastatin 2 mg</title>
            <description>Pitavastatin 2 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Pravastatin 20 mg</title>
            <description>Pravastatin 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Pitavastatin 4 mg</title>
            <description>Pitavastatin 4 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Pravastatin 40 mg</title>
            <description>Pravastatin 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in TC</title>
          <description>Percent change from baseline in total cholesterol (TC)</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="210"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.19" spread="8.899"/>
                    <measurement group_id="O2" value="-15.34" spread="11.037"/>
                    <measurement group_id="O3" value="-26.68" spread="9.429"/>
                    <measurement group_id="O4" value="-20.61" spread="8.426"/>
                    <measurement group_id="O5" value="-30.75" spread="10.461"/>
                    <measurement group_id="O6" value="-24.07" spread="10.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pitavastatin 1 mg</title>
          <description>Pitavastatin 1 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Pravastatin 10 mg</title>
          <description>Pravastatin 10 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>Pitavastatin 2 mg</title>
          <description>Pitavastatin 2 mg once daily</description>
        </group>
        <group group_id="E4">
          <title>Pravastatin 20 mg</title>
          <description>Pravastatin 20 mg once daily</description>
        </group>
        <group group_id="E5">
          <title>Pitavastatin 4 mg</title>
          <description>Pitavastatin 4 mg once daily</description>
        </group>
        <group group_id="E6">
          <title>Pravastatin 40 mg</title>
          <description>Pravastatin 40 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="2"/>
                <counts group_id="E4" subjects_affected="1"/>
                <counts group_id="E5" subjects_affected="3"/>
                <counts group_id="E6" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59"/>
                <counts group_id="E2" subjects_affected="36"/>
                <counts group_id="E3" subjects_affected="62"/>
                <counts group_id="E4" subjects_affected="24"/>
                <counts group_id="E5" subjects_affected="52"/>
                <counts group_id="E6" subjects_affected="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bill Arana</name_or_title>
      <organization>Kowa Research Institute</organization>
      <phone>9194331600</phone>
      <email>barana@kowaus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

